INFORMATION BY CANCER TYPE

Skin

Associating Genes With Melanoma Risk
BY Maria T. Landi, M.D., Ph.D.
Maria T. Landi, M.D., Ph.D., principal investigator at the National Cancer Institute (NCI) and National Institutes of Health (NIH) discusses a recent study that identified genetic variations that may be linked with increased melanoma risk. 
Intralesional Combinations Are Promising in Melanoma
BY Danielle Bucco
Intralesional therapies – those delivered directly to the tumor site – used in conjunction with checkpoint inhibitors have shown improvements to the treatment of people with melanoma, says Robert Andtbacka, M.D., in a presentation at the 2017 World Congress of Melanoma.
Care to Comment on Draft USPSTF Statement on Sun Protection?
BY Mindy Waizer
Members of the public can submit comments to the U.S. Preventive Services Task Force (USPSTF) on its draft recommendation statement on sun protection until Nov. 6, 2017.
Opdivo Granted Priority Review for Post-Surgical Melanoma Treatment
BY Jason Harris
Opdivo (nivolumab) was granted a priority review to a supplemental biologics license application (sBLA) to treat patients with melanoma who have a high risk of disease recurrence after complete surgical resection, according to Bristol-Myers Squibb (BMS), the company that makes the drug.
 
Stubbornness Will Get You Through Cancer
BY Barbara Tako
Seven-year cancer survivor shares tips to help you get through cancer.
Challenges Remain in Melanoma Treatment, Expert Says
BY Angelica Welch
Merrick I. Ross, M.D., discussed key issues in melanoma as the treatment paradigm continues to change.
 
Moving Forward Through Fear of Recurrence
BY Barbara Tako
Breast cancer survivor shares how she copes with fear of recurrence while coping with her mom's breast cancer death and other life changes.
Pen-Like Device May Help Detect Melanoma
BY Brielle Urciuoli
Patients and providers can evaluate lesions within seconds by running the tip of the device over their skin, and then link the results to a user-friendly smartphone app.
Drug Pair Benefits Patients With Melanoma Who Progressed on Prior Therapy
Combination therapy of Opdivo (nivolumab) and LAG-3 inhibitor relatlimab (BMS-986016) benefitted half of the patients with melanoma who previously progressed on an anti-PD-1 or anti-PD-L1 therapy, according to recent results from a dose-expansion study.  
When to Stop Immunotherapy Treatment for Melanoma
BY Yania Jansen
Yania Jansen, surgical trainee at Vrije Universiteit Brussel, in Brussels, Belgium, discusses the possibility of stopping treatment with Keytruda (pembrolizumab) for patients with melanoma.
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Skin CURE discussion group.
Search Cancer Drugs & Terms
Treatment
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Skin Cancer Treatment (PDQ®)
Expert-reviewed information summary about the treatment of skin cancer.
Prevention, Genetics, Causes
Information related to prevention, genetics, risk factors
Skin Cancer Prevention (PDQ®)
Expert-reviewed information summary about factors that may influence the risk of developing skin cancer and about research aimed at the prevention of this disease.
Screening and Testing
Information about methods of cancer detection including new imaging technologies, tumor markers, and biopsy procedures
Skin Cancer Screening (PDQ®)
Expert-reviewed information summary about tests used to detect or screen for skin cancer.
x
//For side ad protocol